Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Sarcoma Clinical Trial

Official title: Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Status Completed

Clinical Trial Summary

The goal of this clinical research study is to find the highest tolerable dose of radium-223 dichloride that can be given to patients with osteosarcoma. Radium-223 chloride is designed to work like radiation therapy in cells that are actively making bone. It is designed to target new bone growth in and around bone cancer and may kill cancer cells.

Clinical Trial Description

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II. If you are found to be eligible to take part in this study, you will be assigned to a dose level of radium-223 dichloride based on when you join this study. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of radium-223 dichloride is found. If you are enrolled in the Phase II portion, you will receive radium-223 dichloride at the highest dose that was tolerated in the Phase I portion. Study Drug Administration: You will receive radium-223 chloride by vein over several minutes on Day 1 of each 4-week cycle. You should drink plenty of fluids before each study drug dose. You and your caregivers will receive spoken and written instructions about safety precautions after receiving this drug. Study Visits: At all study visits, you will be asked about any drugs you may be taking and if you have had any side effects from them. On Day 1 of Cycle 2-6: - You will have a physical exam, including measurement of your vital signs - You will complete a brief questionnaire about any pain that you may be experiencing. This questionnaire should take about 5-10 minutes to complete. - Your performance status will be recorded. - Blood (about 1 tablespoon) will be drawn for routine tests. - If you can become pregnant, you will have a urine or blood pregnancy test. If the doctor thinks it is needed, you will also have an ultrasound to check for pregnancy. To take part in this study, you cannot be pregnant. Within 1-3 weeks after Cycle 3: - You will have scans such as a bone scan and CT or MRI scan to check the status of the disease. - Blood (about 1 tablespoon) will be drawn for routine tests. You may have other routine tests done, including a pregnancy test, if the study doctor thinks it is needed. Length of Study Drug Dosing: You may continue taking the study drug for up to 6 cycles. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. Your participation in this study will be over once you have completed the end-of-dosing visit (and follow-up visits if applicable). End-of-Dosing Visit: About 30 days after your last study drug dose: - You will be asked about any drugs you may be taking and if you have had any side effects from them. - You will have a physical exam, including measurement of your vital signs. - You will complete a brief questionnaire about any pain that you may be experiencing. This questionnaire should take about 5-10 minutes to complete. - Your performance status will be recorded. - Blood (about 1 tablespoon) will be drawn for routine tests. - You will have scans such as a bone scan and CT or MRI scan to check the status of the disease. Follow-Up Visits: If you are younger than 18 years old, your height and weight will be measured 1 time a year until you turn 21. These measurements may stop earlier if your height stays about the same for 2 years in a row. Information about your health status and any side effects (especially related to your bones) will be collected and reported to the study staff every year. This is an investigational study. Radium-223 dichloride is commercially available and FDA approved for the treatment of certain types of prostate cancer. It is currently being used for research purposes only. Up to 20 patients will be enrolled in this study. All will be enrolled at MD Anderson. ;

Related Conditions & MeSH terms

• Osteosarcoma
• Sarcoma

• NCT number: NCT01833520
• Study type: Interventional
• Source: M.D. Anderson Cancer Center
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 16, 2013
• Completion date: April 8, 2020